Remus Vezan
Director/Board Member at Carina Biotech Pty Ltd.
Remus Vezan active positions
Companies | Position | Start | End |
---|---|---|---|
Carina Biotech Pty Ltd.
Carina Biotech Pty Ltd. BiotechnologyHealth Technology Carina Biotech Pty Ltd. is an immuno-oncology company based in Mawson Lakes, Australia. The Australian company is developing CAR-T and other adoptive cell therapies to treat solid cancers. Carina Biotech has a deep pipeline of CAR-T programs, including its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer. The private company aims to improve access to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects. Carina Biotech also has a fully integrated, proprietary manufacturing process that has both reduced manufacturing time and improved CAR-T cell quality, capable of delivering robust “serial-killing” CAR-T cells to patients. The CEO of the company is Deborah A. Rathjen. | Director/Board Member | 2023-06-04 | - |
Independent Dir/Board Member | 2023-06-04 | - |
Career history of Remus Vezan
Training of Remus Vezan
University of Medicine | Doctorate Degree |
Statistics
International
Australia | 2 |
Netherlands | 2 |
Operational
Director/Board Member | 1 |
Independent Dir/Board Member | 1 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Carina Biotech Pty Ltd.
Carina Biotech Pty Ltd. BiotechnologyHealth Technology Carina Biotech Pty Ltd. is an immuno-oncology company based in Mawson Lakes, Australia. The Australian company is developing CAR-T and other adoptive cell therapies to treat solid cancers. Carina Biotech has a deep pipeline of CAR-T programs, including its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer. The private company aims to improve access to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects. Carina Biotech also has a fully integrated, proprietary manufacturing process that has both reduced manufacturing time and improved CAR-T cell quality, capable of delivering robust “serial-killing” CAR-T cells to patients. The CEO of the company is Deborah A. Rathjen. | Health Technology |
- Stock Market
- Insiders
- Remus Vezan
- Experience